Atopic dermatitis: Comorbidities and associated diseases

Authors:: Jonathan I Silverberg, MD, PhD, MPH; William Howe, MD
Section Editors:: Robert P Dellavalle, MD, PhD, MSPH; Moise L Levy, MD; Joseph Fowler, MD
Deputy Editors:: Zehra Hussain, MD, FACP; Rosamaria Corona, MD, DSc

Literature review current through: Apr 2025. | This topic last updated: Jul 09, 2024.

INTRODUCTION —

Atopic dermatitis (AD) is a chronic, pruritic, inflammatory skin disease that commonly affects both children and adults. It is widely recognized that AD carries an increased risk of progression to other atopic diseases, including asthma, allergic rhinitis, allergic rhinoconjunctivitis, and food allergy (the so-called "atopic march") [1]. However, AD has also been associated with a number of nonallergic disorders, including autoimmune, metabolic, and psychiatric disorders [2-6].

This topic will discuss the allergic and nonallergic comorbidities of AD. The pathogenesis, clinical manifestations, diagnosis, and treatment of AD are discussed separately.

●(See "Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis".)

●(See "Treatment of atopic dermatitis (eczema)".)

●(See "Management of severe, refractory atopic dermatitis (eczema) in children".)

●(See "Evaluation and management of severe refractory atopic dermatitis (eczema) in adults".)

ALLERGIC RHINITIS, ASTHMA, AND FOOD ALLERGY —

Patients with AD and a genetic predisposition to produce immunoglobulin E (IgE) following exposure to allergens may develop a typical sequence of AD, allergic rhinitis/conjunctivitis, asthma, and food allergy at certain ages (the so-called "atopic march") [7-9]. Multiple studies indicated that the risk of developing respiratory allergies is inversely associated with the age of onset of AD. In a Canadian cohort of 2311 children with AD, allergic sensitization detected by skin prick testing at age one year was associated with a sevenfold increased risk of asthma at age three compared with absence of allergic sensitization (relative risk [RR] 7.04, 95% CI 4.13-11.99) [10].

●Asthma – The association between AD and asthma is well established. The prevalence of asthma in adults with AD is estimated to be approximately 25 percent [2]. The risk of asthma is higher in patients with severe AD compared with patients with mild or moderate disease [2] and in patients with AD persisting into adolescence [11].

●Food allergy – In a meta-analysis of 320 observational studies including over 225,000 individuals with AD and over 1.1 million individuals without AD, the pooled prevalences of food sensitivity, food allergy, and challenge-proven food allergy were 48.4 percent (95% CI 43.7-53.2), 32.7 percent (95% CI 28.8-36.6), and 40.7 percent (95% CI 34.1-47.5), respectively, among patients with AD compared with 17.9 percent (95% CI 12.7-23.7), 9.4 percent (95% CI 7.8-11.4), and 15.5 percent (95% CI 7.9-25.2), respectively, among patients without AD [12]. The prevalence of food sensitivity and food allergy was higher in children ≤2 years of age and in individuals with severe AD.

Patients with AD also have an increased risk of food-induced urticaria/anaphylaxis [13,14], eosinophilic esophagitis, and chronic rhinosinusitis/nasal polyps [15]. (See "Role of food and environmental allergies in atopic dermatitis (eczema)".)

Whether there is a cause-effect relationship between AD and subsequent development of atopic and allergic comorbidities is still debated. The observation that the prevalence of asthma and food allergies increases with increasing AD severity supports the hypothesis that epicutaneous sensitization to allergens, including food allergens (eg, peanut antigen in household dust), can occur in early life in children with AD due to the defective skin barrier [16-21]. However, food sensitization is clinically irrelevant for the course of AD in most cases, and serum IgE should not be used for the diagnosis of food allergy in the absence of clinical reactions to the ingestion of a certain food. (See "Food allergy in children: Prevalence, natural history, and monitoring for resolution".)

ICHTHYOSIS VULGARIS —

Loss-of-function variants in the filaggrin gene (FLG), which causes ichthyosis vulgaris, confer an increased risk of developing AD and are associated with early-onset, moderate to severe, and persistent eczema [22-24]. (See "Ichthyosis vulgaris".)

It is estimated that approximately 10 to 30 percent of patients with AD also have ichthyosis vulgaris [25,26]. These patients usually show palmar hyperlinearity (picture 1 and picture 2) and keratosis pilaris (picture 3 and picture 4). (See "Keratosis pilaris".)

EYE DISEASES —

Ocular comorbidities occurring in patients with AD include atopic keratoconjunctivitis (AKC) and vernal keratoconjunctivitis (VKC). AKC is a chronic, allergic, ocular disease that most often occurs in adults with a history of AD [27]. VKC most commonly occurs in children living in warm, dry, subtropical climates [28]. Ocular itching, burning, tearing, and mucus discharge are common symptoms. Complications include keratoconus, infectious keratitis, and blepharitis. (See "Atopic keratoconjunctivitis" and "Vernal keratoconjunctivitis".)

AUTOIMMUNE DISORDERS —

A large body of evidence supports the association of AD with cutaneous and noncutaneous autoimmune disorders.

●A Danish study using data on over 8000 patients with AD and over 40,000 age- and sex-matched controls from nationwide health registers found a statistically significant association between AD and alopecia areata, vitiligo, rheumatoid arthritis, and Sjögren's disease [29].

●Similar results were provided by a Swedish population-based case-control study that included over 104,000 cases of AD matched with over 1 million controls from the general population [30]. AD was associated with a twofold increased risk of any autoimmune disorder (odds ratio [OR] 1.97, 95% CI 1.93-2.01).

●A meta-analysis of nine observational studies found an approximately 30 percent increased risk of rheumatoid arthritis in patients with AD (OR 1.28, 95% CI 1.07-1.53) [31]. Of note, this association appeared to be unidirectional as no increased risk of AD was found in studies assessing comorbidities in patients with rheumatoid arthritis.

PSYCHIATRIC DISORDERS —

There is a growing body of evidence that a number of psychiatric disorders and symptoms, including impaired psychosocial functioning, attention deficit hyperactivity disorder, learning disability, depression, and anxiety disorders, are more common among adults and children with AD than in the general population [32-35]. The association of AD with psychosocial distress and other psychiatric disorders may be influenced by the perceived disease severity and other factors that negatively affect quality of life, such as the loss of sleep, disabling pruritus, social embarrassment, and impaired social functioning [33,36].

Attention deficit hyperactivity disorder — The results of a 2010 systematic review of 20 studies including over 170,000 individuals and several subsequent observational studies suggest an association between AD and attention deficit hyperactivity disorder in children as well as in adults [32,37-42]. The mechanisms underlying attention deficit hyperactivity disorder and AD are unknown. Sleep disturbance secondary to nocturnal pruritus, elevated levels of psychologic stress, and the effects of proinflammatory cytokines on brain development are the leading hypotheses to explain this association [40,43,44]. (See "Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis" and "Attention deficit hyperactivity disorder in adults: Epidemiology, clinical features, assessment, and diagnosis".)

Depression and anxiety disorder — Several cohort studies and meta-analyses have found an association between AD and anxiety disorder, depression, suicidal ideation, and attempted suicide in adults and children [32,45-50].

●An analysis of data on over 90,000 children from the 2007 National Survey of Children's Health in the United States found that the prevalence of depression and anxiety disorders among children with AD was significantly higher than among their peers without AD (6.5 versus 3.4 percent, and 7.3 versus 4.1 percent, respectively) and showed an increasing trend with increasing parent- and caregiver-reported severity of dermatitis [32].

●A large longitudinal cohort study using data from the Taiwan National Health Insurance Research Database from 1998 to 2008 assessed the risk of developing major depression or anxiety disorders later in life among more than 8000 adolescents and adults with AD and age- and sex-matched controls [45]. This study found that patients with AD had an increased risk of developing major depression (hazard ratio [HR] 6.56, 95% CI 3.64-11.84), any depressive disorder (HR 5.44, 95% CI 3.99-7.44), and anxiety disorders (HR 3.57, 95% CI 2.55-4.98).

●A 2019 meta-analysis of 37 observational studies found a nearly twofold increased risk of depression in patients with AD compared with individuals without AD (odds ratio [OR] 1.71, 95% CI 1.48-1.98). Based on data from 14 studies, patients with AD were also more likely to have suicidal ideation (OR 1.97, 95% CI 1.19-3.25) [49].

●The association between AD and suicidality was examined in another meta-analysis of 15 observational studies including over 310,000 patients with AD and nearly 4.5 million controls [48]. Compared with persons without AD, patients with AD were found to have an increased risk of suicidal ideation (pooled OR 1.44, 95% CI 1.25-1.65) and suicide attempts (pooled OR 1.36, 95% CI 1.09-1.70). Two of the included studies reporting on the risk of completed suicide among patients with AD provided conflicting results [51,52].

The results of these studies emphasize the need for a multidisciplinary approach to the management of AD that includes patient and parent/caregiver education and psychologic and behavioral support (see "Treatment of atopic dermatitis (eczema)"). Clinicians treating AD should be vigilant for depressive symptoms, especially in patients with severe disease who may need psychiatric referral.

OBESITY AND METABOLIC SYNDROME —

The association between AD and obesity in children and adults is controversial [53-57].

●A 2022 pooled analysis of eight cross-sectional studies found a modest association between AD and obesity (odds ratio [OR] 1.36, 95% CI 1.01-1.83) and a weak association with hypercholesterolemia (OR 1.13, 95% CI 1.09-1.18) [2]. The study also found that AD was associated with a slightly lower risk of type 2 diabetes (OR 0.83, 95% CI 0.76-0.90).

●A 2015 systematic review and meta-analysis of 30 observational studies found that being overweight and obese were associated with increased prevalence of AD in Asia and North America (OR 1.23, 95% CI 1.11-1.41, and OR 1.47, 95% CI 1.21-1.79, respectively) [58].

However, the mechanisms underlying this association are largely unknown.

CARDIOVASCULAR DISEASE —

Previous studies evaluating the association between AD and cardiovascular disease provided conflicting evidence.

●A 2018 large population-based study using 1998 to 2015 data from the United Kingdom Clinical Practice Research Datalink compared the data from nearly 400,000 adult patients with AD and 1.5 million controls matched by age, sex, calendar time, and age and date at cohort entry [59]. This study found that patients with AD and, in particular, those with severe disease (as defined by the type of treatment or specialist referral) had a modest increase in the risk of cardiovascular disease, including myocardial infarction (hazard ratio [HR] 1.37, 95% CI 1.12-1.68), unstable angina (HR 1.41, 95% CI 1.02-1.95), heart failure (HR 1.67, 95% CI 1.36-2.05), atrial fibrillation (HR 1.35, 95% CI 1.14-1.59), and cardiovascular death (HR 1.30, 95% CI 1.10-1.53). Although known confounding factors (eg, body mass index, smoking, hypertension, hyperlipidemia, diabetes) had been adjusted for, the possibility that the results were driven by residual confounding cannot be excluded. In addition, this study could not determine whether AD per se or treatments for AD confer an increased risk of cardiovascular disease. Despite these caveats, this study indicates that in adults presenting with severe AD, screening for cardiovascular disease and known risk factors for cardiovascular disease may be appropriate.

●A 2017 cross-sectional analysis of data from the Canadian Partnership for Tomorrow Project including nearly 260,000 Canadian residents aged 30 to 74 years, of whom approximately 21,000 had a history of AD, found that AD was associated with a mild reduction in the risk of hypertension (odds ratio [OR] 0.87, 95% CI 0.83-0.90), type 2 diabetes (OR 0.78, 95% CI 0.71-0.84), myocardial infarction (OR 0.87, 95% CI 0.75-1.00), and stroke (OR 0.79, 95% CI 0.66-0.95) after adjusting for age, sex, ethnic background, body mass index, smoking 100 cigarettes, weekly alcohol intake, average daily sleep, and weekly physical activity [60].

●A 2017 meta-analysis using adjusted data from 13 studies did not find an association between AD and myocardial infarction (pooled OR 1.03, 95% CI 0.88-1.21), stroke (OR 1.12, 95% CI 0.95-1.32), or hypertension (OR 1.10, 95% CI 0.97-1.24) but found a nearly 50 percent increased risk of angina pectoris (OR 1.48, 95% CI 1.23-1.79) [61].

VENOUS THROMBOEMBOLISM —

AD appears to be associated with a small risk of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism [62-65].

●In a United States study using administrative claims data from 2010 through 2019 from Optum Clinformatics Data Mart that included over 1 million adult patients with AD and matched controls, the VTE incidence was slightly higher among patients with AD compared with patients without AD (0.73 versus 0.59 per 100 person-years) [62].

●A United Kingdom study using data from The Health Improvement Network evaluated the VTE risk in children and adults with AD [63]. In the pediatric cohort that included over 400,000 children with AD and over 1.8 million children without AD, multivariable analysis showed that AD was associated with a 23 percent increased risk for DVT (hazard ratio [HR] 1.23, 95% CI 1.02-1.48) after adjusting for known risk factors for VTE. A similar modest increase in the risk of DVT was found in the adult cohort with over 625,000 patients with AD and nearly 2.7 million controls without AD (HR 1.14, 95% CI 1.11-1.18).

OSTEOPENIA/OSTEOPOROSIS —

The association between AD and bone health impairment is controversial. Observational studies evaluating the association of AD with low bone mass density, osteopenia or osteoporosis, and risk of fractures have reported conflicting results [66].

●A Korean population-based case-control study that included patients <50 years with and without AD did not find a difference in the prevalence of low bone mass density between individuals with AD and those without AD [67].

●A large population-based cohort study using data from the United Kingdom Clinical Practice Research Datalink that included over 520,000 individuals with AD and over 2.5 million individuals without AD found a modest, but statistically significant, association between AD and increased hip, pelvic, spinal, and wrist fractures after adjusting for age, sex, general practice, and date of cohort entry (hazard ratio [HR] 1.10, 99% CI 1.08-1.12) [68].

ANEMIA —

An analysis of caregiver-reported and self-reported data on over 200,000 children and adolescents from the 1997 to 2013 United States National Health Interview Survey found that children with a history of atopic disorders, including eczema, asthma, hay fever, or food allergy, have an increased risk of anemia (for eczema, odds ratio [OR] 1.83, 95% CI 1.58-2.13) [69]. The risk was much higher in children with all four disorders (adjusted OR 7.87, 95% CI 5.17-12). Using laboratory data from the 2014 to 2015 National Health and Nutrition Examination Survey on over 30,000 children, the authors found that children with a current history of atopic eczema had a twofold increased risk of anemia, particularly microcytic anemia (OR 2.03, 95% CI 1.20-3.46).

Another study using data from the Korean universal health insurance system found an increased risk of iron deficiency anemia among children with AD (OR 1.42, 95% CI 1.37-1.47) [70].

Whether anemia in children with AD is related to chronic inflammation or malnutrition secondary to dietary restrictions in patients suspected to have food allergies is unknown. Further ad hoc-designed studies are needed to confirm this association and clarify the underlying mechanisms.

INFLAMMATORY BOWEL DISEASE —

Studies investigating the association between AD and inflammatory bowel disease (IBD) have provided inconsistent results [71-75].

●A population-based study using 1994 to 2015 data from the United Kingdom Health Improvement Network examined the association between AD and IBD in over 400,000 children with AD and 1.8 million matched controls and in over 625,000 adults with AD and nearly 2.7 million matched controls [71]. The study found a 44 percent increased risk of IBD (hazard ratio [HR] 1.44, 95% CI 1.31-1.58) in children with AD and a 34 percent increased risk of IBD (HR 1.34, 95% CI 1.27-1.40) in adults with AD. In both the pediatric and adult cohort, the risk was highest for patients with severe AD (HR 2.59, 95% CI 1.94-3.45, and HR 2.27, 95% CI 1.96-2.64, respectively). (See "Definitions, epidemiology, and risk factors for inflammatory bowel disease".)

●In a retrospective study comparing a cohort of 364 adult patients with AD followed up in a specialized adult AD clinic between 2013 and 2021 with 725 age- and sex-matched patients seen over the same period at the general dermatology clinic at the same institution, the prevalence of IBD in patients with AD was higher than in patients without AD (2.5 versus 1 percent), although the difference was not statistically significant [72]. After adjusting for age, sex, and smoking status by multivariable analysis, patients with AD had an increased risk of IBD (odds ratio [OR] 3.89, 95% CI 1.28-11.85). However, this result should be interpreted with caution due to the small number of IBD cases in the study population and the wide CI of the estimated OR.

●A cohort study using nationwide longitudinal commercial insurance claims data from the Unites States between 2004 and 2020 that included over 123,000 patients with AD did not find an increased risk of IBD among patients with AD compared with patients without chronic inflammatory skin diseases (HR1.02, 95% CI 0.92-1.12 for ulcerative colitis, and HR 1.08, 95% CI 0.94-1.23 for Crohn disease) [73].

●Another nationwide cohort study that included 36,400 patients with AD and 364,000 matched controls without AD from the National Health Insurance Research Database of Taiwan did not find an increased risk of IBD among patients with AD compared with those without AD (16-year cumulative incidence rate 0.047, 95% CI 0.040-0.054, and 16-year cumulative incidence rate 0.047, 95% CI 0.025-0.096, respectively) [74].

SOCIETY GUIDELINE LINKS —

Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Atopic dermatitis".)

SUMMARY

●Atopic dermatitis and risk of comorbid diseases – The association of atopic dermatitis (AD) with other atopic disease, including asthma, allergic rhinitis, allergic rhinoconjunctivitis, and food allergy, is widely recognized. However, there is increasing evidence that AD is associated with a number of nonallergic disorders. (See 'Introduction' above.)

●Other atopic diseases – Patients with AD and a genetic predisposition to produce IgE following exposure to allergens may develop comorbid atopic conditions, including asthma, rhinoconjunctivitis, and food sensitivity or allergy. Although the rate of food sensitization is high in patients with AD and especially in infants and young children, food sensitization is clinically irrelevant for the course of AD in most cases. (See 'Allergic rhinitis, asthma, and food allergy' above.)

●Ichthyosis vulgaris – There is a well-known association between AD and ichthyosis vulgaris, the most common inherited disorder of keratinization caused by loss-of-function variants in the FLG gene, encoding profilaggrin, a protein involved in the formation of the epidermal barrier. (See "Ichthyosis vulgaris".)

●Autoimmune disorders – Multiple lines of evidence support the association of AD with cutaneous and noncutaneous autoimmune disorders, including alopecia areata, vitiligo, and rheumatoid arthritis. (See 'Autoimmune disorders' above.)

●Psychiatric disorders – Impaired psychosocial functioning, attention deficit hyperactivity disorder, learning disability, depression, and anxiety disorders are more common among adults and children with AD than in the general population. They may be influenced by the perceived disease severity, loss of sleep, disabling pruritus, and social embarrassment. (See 'Psychiatric disorders' above.)

Davidson WF, Leung DYM, Beck LA, et al. Report from the National Institute of Allergy and Infectious Diseases workshop on "Atopic dermatitis and the atopic march: Mechanisms and interventions". J Allergy Clin Immunol 2019; 143:894.
Davis DMR, Drucker AM, Alikhan A, et al. American Academy of Dermatology Guidelines: Awareness of comorbidities associated with atopic dermatitis in adults. J Am Acad Dermatol 2022; 86:1335.
Paller A, Jaworski JC, Simpson EL, et al. Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders. Am J Clin Dermatol 2018; 19:821.
Brunner PM, Silverberg JI, Guttman-Yassky E, et al. Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder. J Invest Dermatol 2017; 137:18.
Thijs JL, Strickland I, Bruijnzeel-Koomen CAFM, et al. Serum biomarker profiles suggest that atopic dermatitis is a systemic disease. J Allergy Clin Immunol 2018; 141:1523.
Thyssen JP, Halling AS, Schmid-Grendelmeier P, et al. Comorbidities of atopic dermatitis-what does the evidence say? J Allergy Clin Immunol 2023; 151:1155.
von Kobyletzki LB, Bornehag CG, Hasselgren M, et al. Eczema in early childhood is strongly associated with the development of asthma and rhinitis in a prospective cohort. BMC Dermatol 2012; 12:11.
Bantz SK, Zhu Z, Zheng T. The Atopic March: Progression from Atopic Dermatitis to Allergic Rhinitis and Asthma. J Clin Cell Immunol 2014; 5.
Spergel JM. From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol 2010; 105:99.
Tran MM, Lefebvre DL, Dharma C, et al. Predicting the atopic march: Results from the Canadian Healthy Infant Longitudinal Development Study. J Allergy Clin Immunol 2018; 141:601.
Paternoster L, Savenije OEM, Heron J, et al. Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohorts. J Allergy Clin Immunol 2018; 141:964.
Christensen MO, Barakji YA, Loft N, et al. Prevalence of and association between atopic dermatitis and food sensitivity, food allergy and challenge-proven food allergy: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2023; 37:984.
Eigenmann PA, Calza AM. Diagnosis of IgE-mediated food allergy among Swiss children with atopic dermatitis. Pediatr Allergy Immunol 2000; 11:95.
García C, El-Qutob D, Martorell A, et al. Sensitization in early age to food allergens in children with atopic dermatitis. Allergol Immunopathol (Madr) 2007; 35:15.
Paller AS, Mina-Osorio P, Vekeman F, et al. Prevalence of type 2 inflammatory diseases in pediatric patients with atopic dermatitis: Real-world evidence. J Am Acad Dermatol 2022; 86:758.
Lowe AJ, Leung DYM, Tang MLK, et al. The skin as a target for prevention of the atopic march. Ann Allergy Asthma Immunol 2018; 120:145.
Dharmage SC, Lowe AJ, Matheson MC, et al. Atopic dermatitis and the atopic march revisited. Allergy 2014; 69:17.
Bartnikas LM, Gurish MF, Burton OT, et al. Epicutaneous sensitization results in IgE-dependent intestinal mast cell expansion and food-induced anaphylaxis. J Allergy Clin Immunol 2013; 131:451.
Brough HA, Simpson A, Makinson K, et al. Peanut allergy: effect of environmental peanut exposure in children with filaggrin loss-of-function mutations. J Allergy Clin Immunol 2014; 134:867.
Brough HA, Liu AH, Sicherer S, et al. Atopic dermatitis increases the effect of exposure to peanut antigen in dust on peanut sensitization and likely peanut allergy. J Allergy Clin Immunol 2015; 135:164.
Brough HA, Kull I, Richards K, et al. Environmental peanut exposure increases the risk of peanut sensitization in high-risk children. Clin Exp Allergy 2018; 48:586.
Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38:441.
van den Oord RA, Sheikh A. Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta-analysis. BMJ 2009; 339:b2433.
Weidinger S, O'Sullivan M, Illig T, et al. Filaggrin mutations, atopic eczema, hay fever, and asthma in children. J Allergy Clin Immunol 2008; 121:1203.
Bremmer SF, Hanifin JM, Simpson EL. Clinical detection of ichthyosis vulgaris in an atopic dermatitis clinic: implications for allergic respiratory disease and prognosis. J Am Acad Dermatol 2008; 59:72.
Tay YK, Kong KH, Khoo L, et al. The prevalence and descriptive epidemiology of atopic dermatitis in Singapore school children. Br J Dermatol 2002; 146:101.
Chen JJ, Applebaum DS, Sun GS, Pflugfelder SC. Atopic keratoconjunctivitis: A review. J Am Acad Dermatol 2014; 70:569.
Pattnaik L, Acharya L. A comprehensive review on vernal keratoconjunctivitis with emphasis on proteomics. Life Sci 2015; 128:47.
Narla S, Silverberg JI. Association between atopic dermatitis and autoimmune disorders in US adults and children: A cross-sectional study. J Am Acad Dermatol 2019; 80:382.
Ivert LU, Wahlgren CF, Lindelöf B, et al. Association between atopic dermatitis and autoimmune diseases: a population-based case-control study. Br J Dermatol 2021; 185:335.
Williams RC, Brako MYO, Guo W, et al. The uni-directional association of atopic dermatitis and rheumatoid arthritis: a systematic review and meta-analysis. Arch Dermatol Res 2023; 315:2261.
Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol 2013; 131:428.
Slattery MJ, Essex MJ, Paletz EM, et al. Depression, anxiety, and dermatologic quality of life in adolescents with atopic dermatitis. J Allergy Clin Immunol 2011; 128:668.
Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract 2006; 60:984.
Wan J, Mitra N, Hooper SR, et al. Association of Atopic Dermatitis Severity With Learning Disability in Children. JAMA Dermatol 2021; 157:1.
Radtke S, Grossberg AL, Wan J. Mental health comorbidity in youth with atopic dermatitis: A narrative review of possible mechanisms. Pediatr Dermatol 2023; 40:977.
Chen MH, Su TP, Chen YS, et al. Is atopy in early childhood a risk factor for ADHD and ASD? a longitudinal study. J Psychosom Res 2014; 77:316.
Shyu CS, Lin HK, Lin CH, Fu LS. Prevalence of attention-deficit/hyperactivity disorder in patients with pediatric allergic disorders: a nationwide, population-based study. J Microbiol Immunol Infect 2012; 45:237.
Schmitt J, Buske-Kirschbaum A, Roessner V. Is atopic disease a risk factor for attention-deficit/hyperactivity disorder? A systematic review. Allergy 2010; 65:1506.
Strom MA, Fishbein AB, Paller AS, Silverberg JI. Association between atopic dermatitis and attention deficit hyperactivity disorder in U.S. children and adults. Br J Dermatol 2016; 175:920.
Fan R, Leasure AC, Damsky W, Cohen JM. Association of atopic dermatitis with attention-deficit hyperactivity disorder among US adults in the "All of Us" research program: A case-control study. J Am Acad Dermatol 2022; 87:691.
Wan J, Wang S, Shin DB, et al. Neuropsychiatric disorders in adults with atopic dermatitis: A population-based cohort study. J Eur Acad Dermatol Venereol 2024; 38:543.
Romanos M, Gerlach M, Warnke A, Schmitt J. Association of attention-deficit/hyperactivity disorder and atopic eczema modified by sleep disturbance in a large population-based sample. J Epidemiol Community Health 2010; 64:269.
Buske-Kirschbaum A, Schmitt J, Plessow F, et al. Psychoendocrine and psychoneuroimmunological mechanisms in the comorbidity of atopic eczema and attention deficit/hyperactivity disorder. Psychoneuroendocrinology 2013; 38:12.
Cheng CM, Hsu JW, Huang KL, et al. Risk of developing major depressive disorder and anxiety disorders among adolescents and adults with atopic dermatitis: a nationwide longitudinal study. J Affect Disord 2015; 178:60.
Bao Q, Chen L, Lu Z, et al. Association between eczema and risk of depression: A systematic review and meta-analysis of 188,495 participants. J Affect Disord 2018; 238:458.
Rønnstad ATM, Halling-Overgaard AS, Hamann CR, et al. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis. J Am Acad Dermatol 2018; 79:448.
Sandhu JK, Wu KK, Bui TL, Armstrong AW. Association Between Atopic Dermatitis and Suicidality: A Systematic Review and Meta-analysis. JAMA Dermatol 2019; 155:178.
Patel KR, Immaneni S, Singam V, et al. Association between atopic dermatitis, depression, and suicidal ideation: A systematic review and meta-analysis. J Am Acad Dermatol 2019; 80:402.
Treudler R, Zeynalova S, Riedel-Heller SG, et al. Depression, anxiety and quality of life in subjects with atopic eczema in a population-based cross-sectional study in Germany. J Eur Acad Dermatol Venereol 2020; 34:810.
Singhal A, Ross J, Seminog O, et al. Risk of self-harm and suicide in people with specific psychiatric and physical disorders: comparisons between disorders using English national record linkage. J R Soc Med 2014; 107:194.
Thyssen JP, Hamann CR, Linneberg A, et al. Atopic dermatitis is associated with anxiety, depression, and suicidal ideation, but not with psychiatric hospitalization or suicide. Allergy 2018; 73:214.
Silverberg JI, Becker L, Kwasny M, et al. Central obesity and high blood pressure in pediatric patients with atopic dermatitis. JAMA Dermatol 2015; 151:144.
Silverberg JI, Kleiman E, Lev-Tov H, et al. Association between obesity and atopic dermatitis in childhood: a case-control study. J Allergy Clin Immunol 2011; 127:1180.
Silverberg JI, Silverberg NB, Lee-Wong M. Association between atopic dermatitis and obesity in adulthood. Br J Dermatol 2012; 166:498.
Kusunoki T, Morimoto T, Nishikomori R, et al. Obesity and the prevalence of allergic diseases in schoolchildren. Pediatr Allergy Immunol 2008; 19:527.
Luo X, Xiang J, Dong X, et al. Association between obesity and atopic disorders in Chinese adults: an individually matched case-control study. BMC Public Health 2013; 13:12.
Zhang A, Silverberg JI. Association of atopic dermatitis with being overweight and obese: a systematic review and metaanalysis. J Am Acad Dermatol 2015; 72:606.
Silverwood RJ, Forbes HJ, Abuabara K, et al. Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study. BMJ 2018; 361:k1786.
Drucker AM, Qureshi AA, Dummer TJB, et al. Atopic dermatitis and risk of hypertension, type 2 diabetes, myocardial infarction and stroke in a cross-sectional analysis from the Canadian Partnership for Tomorrow Project. Br J Dermatol 2017; 177:1043.
Thyssen JP, Halling-Overgaard AS, Andersen YMF, et al. The association with cardiovascular disease and type 2 diabetes in adults with atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol 2018; 178:1272.
Merola JF, Ertmer B, Liang H, et al. Venous thromboembolism risk is lower in patients with atopic dermatitis than other immune-mediated inflammatory diseases: A retrospective, observational, comparative cohort study using US claims data. J Am Acad Dermatol 2024; 90:935.
Wan J, Fuxench ZCC, Wang S, et al. Incidence of Cardiovascular Disease and Venous Thromboembolism in Patients With Atopic Dermatitis. J Allergy Clin Immunol Pract 2023; 11:3123.
Warren RB, Basey V, Lynam A, et al. The risk of venous thromboembolism in atopic dermatitis: a matched cohort analysis in UK primary care. Br J Dermatol 2023; 189:427.
Chen TL, Huang WT, Loh CH, et al. Risk of Venous Thromboembolism Among Adults With Atopic Dermatitis. JAMA Dermatol 2023; 159:720.
Mukovozov IM, Morra DE, Giustini D, et al. Atopic dermatitis and bone health: a systematic review. J Eur Acad Dermatol Venereol 2021; 35:615.
Kim S, Choi J, Cho MK, et al. Bone mineral density and osteoporosis risk in young adults with atopic dermatitis. Sci Rep 2021; 11:24228.
Lowe KE, Mansfield KE, Delmestri A, et al. Atopic eczema and fracture risk in adults: A population-based cohort study. J Allergy Clin Immunol 2020; 145:563.
Drury KE, Schaeffer M, Silverberg JI. Association Between Atopic Disease and Anemia in US Children. JAMA Pediatr 2016; 170:29.
Rhew K, Oh JM. Association between atopic disease and anemia in pediatrics: a cross-sectional study. BMC Pediatr 2019; 19:455.
Chiesa Fuxench ZC, Wan J, Wang S, et al. Risk of Inflammatory Bowel Disease in Patients With Atopic Dermatitis. JAMA Dermatol 2023; 159:1085.
Rom H, Snir Y, Schwartz N, et al. The association between atopic dermatitis and inflammatory bowel disease in adults: A cross-sectional study in a specialized atopic dermatitis clinic. J Eur Acad Dermatol Venereol 2024; 38:1357.
Schneeweiss MC, Kirchgesner J, Wyss R, et al. Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study: Classification: Epidemiology. Br J Dermatol 2022; 187:692.
Weng YC, Juan CK, Ho HJ, et al. Atopic dermatitis does not increase the risk of inflammatory bowel disease: A nationwide cohort study. J Dermatol 2021; 48:168.
Lerchova T, Størdal K, Andersson B, et al. Atopic Dermatitis in Early Childhood and Risk of Inflammatory Bowel Disease: A Scandinavian Birth Cohort Study. J Pediatr 2024; 270:114027.

Topic 143875 Version 4.0

خرید پکیج

Atopic dermatitis: Comorbidities and associated diseases

References